



Complete Summary

GUIDELINE TITLE

Treatment of obesity.

BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Treatment of obesity. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Nov 5 [Various]. [3 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Treatment of obesity. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2006 Sep 20 [Various].

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
CONTRAINDICATIONS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Obesity

GUIDELINE CATEGORY

Counseling
Evaluation
Management
Treatment

CLINICAL SPECIALTY

Endocrinology
Family Practice
Gastroenterology
Internal Medicine
Nutrition
Pediatrics
Surgery

INTENDED USERS

Dietitians
Health Care Providers
Nurses
Physicians

GUIDELINE OBJECTIVE(S)

Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.

TARGET POPULATION

People who are obese

INTERVENTIONS AND PRACTICES CONSIDERED

Evaluation

Assessing the need for treatment using body mass index (BMI)

Counseling/Treatment

1. Basic treatment (lifestyle counseling regarding behavior, diet, and exercise)
2. Basic treatment plus a very low calorie diet
3. Drug treatment (orlistat, sibutramine, rimonabant)
4. Surgical treatment (gastroplasty, gastric banding, or gastric bypass)
5. Follow-up

MAJOR OUTCOMES CONSIDERED

- Morbidity associated with obesity
- Efficacy of treatment
 - Weight loss
 - Maintenance of weight loss
 - Amount of weight regained
 - Prevention of progression of obesity
 - Effect of treatment on comorbidities
- Adverse effects or complications associated with treatment

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Classification of the Quality of Evidence

Code	Quality of Evidence	Definition
A	High	Further research is very unlikely to change our confidence in the estimate of effect. <ul style="list-style-type: none">• Several high-quality studies with consistent results• In special cases: one large, high-quality multi-centre trial
B	Moderate	Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate. <ul style="list-style-type: none">• One high-quality study• Several studies with some limitations
C	Low	Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.

Code	Quality of Evidence	Definition
		<ul style="list-style-type: none"> One or more studies with severe limitations
D	Very Low	<p>Any estimate of effect is very uncertain.</p> <ul style="list-style-type: none"> Expert opinion No direct research evidence One or more studies with very severe limitations

GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 (modified by the EBM Guidelines Editorial Team).

METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses
Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

Cost analyses were reviewed.

In a cost-utility analysis, the net cost per quality-adjusted life years (QALY) was 6,289 Great Britain pounds (GBP) for gastric bypass (Roux-en-Y), 10,237 GBP for vertical banded gastroplasty, and 8,527 GBP for silicone adjustable gastric banding as compared with non-surgical management. Gastric bypass appears to have a modest net cost per QALY gained compared to vertical banded gastroplasty (742 GBP/QALY), when silicone adjustable gastric banding has a large net cost per QALY gained compared to gastric bypass (256,856 GBP/QALY).

METHOD OF GUIDELINE VALIDATION

Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not stated

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

Assessment of the Need of Treatment

- Overweight (mild obesity): body mass index (BMI) 25 to 30 kg/m²
 - Usually no treatment is indicated.
 - Treatment is indicated in central obesity, metabolic syndrome (see the Finnish Medical Society Duodecim guideline "Metabolic Syndrome"), or non-insulin-dependent diabetes.
 - In children even mild obesity should be treated.
- Moderate obesity: BMI 30 to 35 kg/m²
 - Treatment is always indicated if the patient has diabetes, hypertension, hyperlipidaemia, or other associated disease (Douketis et al., 1999) [**B**].
 - A young obese person with good health should be treated. The treatment of middle-aged persons is decided individually according to the available resources.
- Severe obesity: BMI >35 kg/m²
 - Must always be treated

Treatment Principles

- There are effective methods available for the treatment of obesity (Glenny & O'Meara, 1997; Avenell et al., 2004) [**A**].
- The target should be moderate, a 5–10% reduction in weight.
- The patient should have an own desire to make the necessary changes in the dietary and exercise habits.
- Some patients succeed in reducing weight on their own, as they have understood its importance and received the necessary information.
- Many patients require professional counselling and support.

Selecting the Method of Treatment

1. Basic treatment consisting of a gradual and permanent change in living habits by counselling and guidance.
 - Well suited for patients with mild and moderate obesity and for the majority of patients with severe obesity; **should always be included in other forms of conservative treatment.**
2. Basic treatment and a very low calorie diet
 - Well suited for morbid and severe obesity

- A choice in moderate obesity if the basic treatment has been unsuccessful and there is a strong indication for reducing weight (associated diseases)
3. Drugs (orlistat, sibutramine, rimonabant)
 - Do not automatically help all patients
 - An alternative especially if other approaches have been failed
 - Life-style counselling must also be included.
 4. Surgical treatment
 - Suitable only for selected patients with morbid obesity (see criteria below).

Basic Treatment

Organisation

- **Group treatment** is less costly and as effective as individualised treatment
 - At least 10 meetings are arranged with about one-week intervals.
 - Group size 10 to 15 persons
 - The group leader is a nurse or a dietician with special training in the treatment of obesity.

Goals That Can Be Measured

- **The optimal rate of weight reduction is 0.5 kg/week.** As the adipose tissue contains about 30 MJ (7,000 kcal)/kg, a daily reduction of 2,100 kJ (500 kcal) in the energy intake will result in this rate of weight reduction.
- The goal is to reduce weight by 5 to 10%, which already results in significant benefit in the treatment of diseases associated with obesity.
- A permanent result is always aimed at. This means that the changes in living habits must be permanent.
- In growing children, weight should be kept constant so that the growth of height corrects the relative weight.
- There are many treatments with no proven efficacy. Appetite-suppressant drugs may result in a moderate weight reduction but the effect is transient.

Aims and Contents of Counselling

- Changes in knowledge and attitudes
 - Human energy consumption is reduced if the body weight is reduced. In order to sustain the weight that has been achieved **the changes in living habits must be permanent.**
- Changes in meals (Franz et al., 2007; Miller, Kocaja, & Hamilton, 1997) [**A**]
 - Find out the present contents of meals.
 - Reduce intake by about 2,000 kJ (500 kcal) daily.
 - The emphasis is on the reduction of energy intake in the diet by reducing the amount of fat (Pirozzo et al., 2008) [**B**] and by increasing the amount of vegetables.
 - Remember alcohol as a cause of obesity.
 - Small daily changes are effective in the long run.

- Keep three daily meals.
- Changes in physical exercise (Franz et al., 2007; Miller, Koceja, & Hamilton, 1997) [A]
 - The advice depends on the degree of obesity.
 - Exercise during daily activities should be encouraged (climbing up stairs, walking or cycling to work).
 - If a pedometer is used, the target is at least 10,000 steps per day.
- Changes in eating behaviour
 - The most common goal is to change behaviour, not to "hunt kilograms."
 - Identify the circumstances that trigger eating. Craving or hunger?
 - Grocery shopping with a pre-planned list.
 - Reduce temptations (no food in sight!).
 - Do nothing else when eating (such as watch TV, read magazines).
 - Eat slowly.

Very Low Calorie Diet (VLCD)

- Constituents
 - 1,700 to 2,100 kJ (400 to 500 kcal) of energy, a maximum of 3,300 kJ (800 kcal) daily.
 - Protein as needed (at least 50 g daily).
 - Essential fatty acids, trace elements, and vitamins as needed
- Schedule
 - Ready-made commercial formulas that fulfil the VLCD criteria should be used.
 - They are consumed as the only food continuously for 8 to 12 weeks. The diet is discontinued earlier if BMI 25 is reached.
 - The patient is followed up at 1 to 2 week intervals.
 - Suitable for patients with non-insulin-dependent (type 2) diabetes and hypertension. Insulin treatment is stopped or the dose is reduced considerably, and the dose of sulphonylureas is halved (risk of hypoglycaemia!) before starting VLCD. The doses of other drugs need not be reduced.
 - The rate of weight reduction is about 1.5 to 2 kg/week, and the immediate weight reduction is 2 to 2.5 times that on basic treatment.
 - A VLCD alone does not yield permanent results. Basic treatment for permanent life-style changes is applied in the normal fashion.

Drug Treatment for Obesity

- Drugs are not a universal remedy in the management of obesity. They can be tried for patients who have the metabolic syndrome or some other "obesity disease" when lifestyle changes alone have not given sufficient results.
- When prescribing a weight-reducing drug, the patient should also be provided with guidance in lifestyle changes.
- A drug indicated for the treatment of obesity may be used when the patient has body mass index over 30 kg/m² (or over 27 to 28 kg/m², if the patient has diabetes or some other disease requiring weight reduction).
- The patient should be informed that the drug treatment for obesity is aimed to last for several years. After discontinuation of the drug, weight will increase again in most cases.

- Stop the drug, if there has not been a significant weight reduction in 3 months (at least 5% of the baseline weight).

Orlistat

- Orlistat is a lipase inhibitor acting in the digestive tract. It partly prevents the absorption of dietary fat. The drug is not absorbed in the bloodstream.
- Weight reduction in patients who have taken 120 mg of orlistat before main meals has been on the average 3 kg more than with placebo at one year (Padwal, Li & Lau, 2003) [**B**]. The proportion of patients who have lost more than 10% of the baseline weight has been 12 percentage points greater with orlistat than with placebo.
- Due to the mode of action of the drug, low-density lipoprotein (LDL) cholesterol concentration will reduce more than would be achieved with the weight reduction alone.
- When using the drug, a concomitant aim is to limit the proportion of dietary energy intake coming from fat to no more than 30%. The snacks should be low-fat. The patient should receive sufficient dietary counselling.
- Common adverse effects include fatty or oily stools, faecal urgency and oily faecal spotting (>1/10 users).

Sibutramine

- A centrally acting appetite suppressant that inhibits the reuptake of serotonin and noradrenalin
- Weight reduction in patients who have taken 15 mg of sibutramine daily has been on the average 4 kg more than with placebo at one year (Padwal, Li & Lau, 2003) [**B**]. The proportion of patients who have lost more than 10% of the baseline weight at one year has been 15 percentage points greater with sibutramine than with placebo.
- The most common adverse effects include insomnia, nausea, dry mouth and constipation. These have occurred in 7% to 20% of patients using sibutramine.
- Because of the effects on blood pressure and heart rate, the drug is not recommended for patients with cardiovascular diseases.

Rimonabant

- A centrally acting appetite suppressant that blocks the endocannabinoid receptor 1. CB1-receptors are also found in fat cells and in the digestive tract.
- Weight reduction in patients who have taken 20 mg of rimonabant daily has been on the average 5 kg more than with placebo at one year (Curioni & Andre, 2006; Christensen et al., 2007) [**A**]. The proportion of patients who have lost more than 10% of the baseline weight at one year has varied between 17% and 26% with rimonabant compared to placebo, depending on the study.
- The most common adverse effects include nausea, vertigo, diarrhoea, anxiety, depression, fatigue and insomnia.
- Rimonabant should not be prescribed if the patient is concurrently in severe depression. It should be prescribed with caution and the patient should be carefully followed up if he/she has a history of depression.

Surgical Treatment

Criteria

- Age 18 to 60 years
- BMI at least 35 to 40 kg/m²
- An efficient conservative treatment strategy has been tried.
- The patient is cooperative.
- There is no abuse of alcohol or drugs.

Method

- Gastroplasty, gastric banding (Schneider, 2000; Chapman et al., 2002; Health Technology Assessment Database: HTA-20030005, 2004; "Newer techniques," 2003; Health Technology Assessment Database: HTA-20031130, 2004) [**B**], or gastric bypass so that the patient can eat only slowly and small amounts at a time. Laparoscopic procedures are also possible. Surgical treatment is associated with potential complications.
- The operation is not sufficient alone. Adequate preoperative investigations, patient counselling, and follow-up for several years are necessary.
- The outcome of successful surgical treatment is much better than that of conservative treatment (Colquitt et al., 2005; Clegg et al., 2002; "Special report," 2003; "Gastric restrictive surgery," 2000; "Newer techniques," 2003; Nilsen, 2003) [**A**]: the patients reduce 30 to 40 kg of their weight, and the result is long lasting.
- Deficiency of the vitamins B₁₂ and D may develop after gastric bypass surgery.

Related Resources

Refer to the original guideline document for related evidence, including Cochrane reviews and other evidence summaries.

Definitions:

Classification of the Quality of Evidence

Code	Quality of Evidence	Definition
A	High	Further research is very unlikely to change our confidence in the estimate of effect. <ul style="list-style-type: none">• Several high-quality studies with consistent results• In special cases: one large, high-quality multi-centre trial
B	Moderate	Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.

Code	Quality of Evidence	Definition
		<ul style="list-style-type: none"> • One high-quality study • Several studies with some limitations
C	Low	<p>Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.</p> <ul style="list-style-type: none"> • One or more studies with severe limitations
D	Very Low	<p>Any estimate of effect is very uncertain.</p> <ul style="list-style-type: none"> • Expert opinion • No direct research evidence • One or more studies with very severe limitations

GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group 2007 (modified by the EBM Guidelines Editorial Team).

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

[References open in a new window](#)

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

Appropriate assessment and treatment of obesity

POTENTIAL HARMS

- Common adverse effects of orlistat include fatty or oily stools, faecal urgency and oily faecal spotting (>1/10 users).
- The most common adverse effects of sibutramine include insomnia, nausea, dry mouth, and constipation.
- The most common adverse effects of rimonabant include nausea, vertigo, diarrhoea, anxiety, depression, fatigue and insomnia. Rimonabant should be prescribed with caution and the patient should be carefully followed up if he/she has a history of depression.
- There is a risk of hypoglycemia in patients on a very low calorie diet and taking sulphonylureas.
- Surgical treatment is associated with potential complications.
- Deficiency of the vitamins B₁₂ and D may develop after gastric bypass surgery.

CONTRAINDICATIONS

CONTRAINDICATIONS

- Rimonabant should not be prescribed if the patient is concurrently in severe depression.
- Because of the effects on blood pressure and heart rate, sibutramine is not recommended for patients with cardiovascular disease.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Living with Illness

IOM DOMAIN

Effectiveness
Patient-centeredness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Treatment of obesity. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2007 Nov 5 [Various]. [3 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2004 Jun 22 (revised 2007 Nov 5)

GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Author: Pertti Mustajoki

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Treatment of obesity. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2006 Sep 20 [Various].

GUIDELINE AVAILABILITY

This guideline is included in "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: info@ebm-guidelines.com; Web site: www.ebm-guidelines.com.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on September 2, 2005. This NGC summary was updated by ECRI Institute on December 26, 2006 and December 23, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2009 National Guideline Clearinghouse

Date Modified: 2/2/2009

